3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Renal Cell
6
Neoplasm Metastasis
5
Stomach Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Urachal cancer
1
Thrombocytosis
1
Testicular Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
pembrolizumab
31
Nivolumab
12
Cyclophosphamide
10
fludarabine
9
aldesleukin
8
atezolizumab
7
durvalumab
6
Magnetic Resonance Spectroscopy
6
Trastuzumab
5
Specimen Handling
5
Paclitaxel
5
Ipilimumab
5
Docetaxel
5
Biopsy
5
fludarabine phosphate
4
Radiotherapy
4
Interleukin-2
4
Gene Expression Profiling
4
Carboplatin
4
tisotumab vedotin
3
cemiplimab
3
aflibercept
3
Polymerase Chain Reaction
3
Immunoglobulin G
3
Early Intervention, Educational
3
Cisplatin
3
Bevacizumab
3
tremelimumab
2
tislelizumab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Leucovorin
×
Genitourinary
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled